Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-76fb5796d-45l2p Total loading time: 0 Render date: 2024-04-29T17:47:57.108Z Has data issue: false hasContentIssue false

Chapter 10 - Is There a Cannabis-Associated Psychosis Sub-type?

Lessons from Biological Typing in the B-SNIP Project and Implications for Treatment

from Part III - Cannabis and the Brain

Published online by Cambridge University Press:  12 May 2023

By
Godfrey D. Pearlson  and
Matcheri S. Keshavan
Edited by
Deepak Cyril D'Souza ,
David Castle  and
Sir Robin Murray
Deepak Cyril D'Souza
Affiliation:
Staff Psychiatrist, VA Connecticut Healthcare System; Professor of Psychiatry, Yale University School of Medicine
David Castle
Affiliation:
University of Tasmania, Australia
Sir Robin Murray
Affiliation:
Honorary Consultant Psychiatrist, Psychosis Service at the South London and Maudsley NHS Trust; Professor of Psychiatric Research at the Institute of Psychiatry
Get access

Summary

‘Cannabis-associated psychosis’ (CAP) refers to a chronic psychotic illness that arises in the context of significant current or past cannabis use. This chapter is an interrogation of the large-scale, multi-centre cross-sectional study of individuals with an established psychotic illness, the bipolar–schizophrenia network on intermediate phenotypes (B-SNIP). B-SNIP used biological characteristics to sub-divide individuals with psychotic illnesses into distinct sub-group,s known as ‘Biotypes’. A subtype associated with adolescent cannabis exposure, Biotype-3, was characterized to have the distinct profile of a significant excess of adolescent cannabis use histories preceding the onset of psychosis, histories of childhood abuse, distinctly preserved cognition, hippocampal morphological and neurochemical abnormalities, normal evoked and resting electrophysiology, more normal MRI grey matter patterns, near-normal saccades and smooth pursuit eye movements, and the lowest schizophrenia polygenic risk scores. Further work is necessary to study CAP in order to find treatments specific for CAP.

Keywords

cannabiscannabinoidsTHCcannabidiolpsychosisbiotypecognitionbrain structureglutamateGABA
Type
Chapter
Information
Marijuana and Madness , pp. 91 - 106
Publisher: Cambridge University Press
Print publication year: 2023

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Abush, H., Ghose, S., van Enkevort, E. A., et al. (2018). Associations between adolescent cannabis use and brain structure in psychosis. Psychiatry Res Neuroimaging, 276, 53–64.Google Scholar
Aguiar, D. C., Moreira, F. A., Terzian, A. L., et al. (2014). Modulation of defensive behavior by Transient Receptor Potential Vanilloid Type-1 (TRPV1) channels. Neurosci Biobehav Rev, 46, 418–428.CrossRefGoogle ScholarPubMed
Alemany, S. (2014). Psychosis-inducing effects of cannabis are related to both childhood abuse and COMT genotypes. Acta Psychiatr Scand, 129, 54–62.Google Scholar
Antoniades, M., Schoeler, T., Radua, J., et al. (2018). Verbal learning and hippocampal dysfunction in schizophrenia: A meta-analysis. Neurosci Biobehav Rev, 86, 166–175.CrossRefGoogle ScholarPubMed
Atakan, Z., Bhattacharyya, S., Allen, P., et al. (2013). Cannabis affects people differently: Inter-subject variation in the psychotogenic effects of D9-tetrahydrocannabinol: A functional magnetic resonance imaging study with healthy volunteers. Psychol Med, 43, 1255–1267.Google Scholar
Benetti, S., Mechelli, A., Picchioni, M., et al. (2009). Functional integration between the posterior hippocampus and prefrontal cortex is impaired in both first episode schizophrenia and the at risk mental state. Brain, 132, 2426–2436.CrossRefGoogle ScholarPubMed
Bloomfield, M. A., Ashok, A. H., Volkow, N. D., et al. (2016). The effects of Delta(9)-tetrahydrocannabinol on the dopamine system. Nature, 539, 369–377.Google Scholar
Bloomfield, M. A., Morgan, C. J., Egerton, A., et al. (2014). Dopaminergic function in cannabis users and its relationship to cannabis-induced psychotic symptoms. Biol Psychiatry, 75, 470–478.CrossRefGoogle ScholarPubMed
Bolo, N., Zeng, V., Clementz, B. A., et al. (2021). Hippocampal glutamate, verbal episodic memory and intrinsic neural activity in the psychosis spectrum Soc Biol Psychiatry, 89, S345.Google Scholar
Bossong, M. G., Mehta, M. A., van Berckel, B. N., et al. (2015). Further human evidence for striatal dopamine release induced by administration of 9-tetrahydrocannabinol (THC): Selectivity to limbic striatum. Psychopharmacology (Berl), 232, 2723–2729.CrossRefGoogle ScholarPubMed
Boydell, J., Dean, K., Dutta, R., et al. (2007). A comparison of symptoms and family history in schizophrenia with and without prior cannabis use: Implications for the concept of cannabis psychosis. Schizophr Res, 93, 203–210.CrossRefGoogle ScholarPubMed
Carr, C. P., Martins, C. M., Stingel, A. M., et al. (2013). The role of early life stress in adult psychiatric disorders: A systematic review according to childhood trauma subtypes. J Nerv Ment Dis, 201, 1007–1020.Google Scholar
Cheer, J. F., Wassum, K. M., Heien, M. L., et al. (2004). Cannabinoids enhance subsecond dopamine release in the nucleus accumbens of awake rats. J Neurosci, 24, 4393–4400.CrossRefGoogle ScholarPubMed
Clementz, B. A., Parker, D. A., Trotti, R. L., et al. (2022). Psychosis biotypes: Replication and validation from the B-SNIP Consortium. Schizophr Bull, 48, 56–68.Google Scholar
Clementz, B. A., Sweeney, J. A., Hamm, J. P., et al. (2016). Identification of distinct psychosis biotypes using brain-based biomarkers. Am J Psychiatry, 173, 373–383.Google Scholar
Colizzi, M., Iyegbe, C., and Powell, J., et al. (2015). Interaction between DRD2 and AKT1 genetic variations on risk of psychosis in cannabis users: A case control study. NPJ Schizophren, 1, 15049.CrossRefGoogle ScholarPubMed
Colizzi, M., Weltens, N., McGuire, P., et al. (2019). Does cannabis induce psychosis by altering glutamate signaling in the striatum? Schizophr Bull, 45, S166–S167.Google Scholar
Crane, N. A., Schuster, R. M., Fusar-Poli, P., et al. (2013). Effects of cannabis on neurocognitive functioning: Recent advances, neurodevelopmental influences, and sex differences. Neuropsychol Rev, 23, 117–137.Google Scholar
Cunha, P. J., Rosa, P. G. P., and Ayres Ade, M. (2013). Cannabis use, cognition and brain structure in first-episode psychosis. Schizophr Res, 147, 209–215.CrossRefGoogle ScholarPubMed
D’Souza, D. C., Perry, E., MacDougall, L., et al. (2004). The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: Implications for psychosis. Neuropsychopharmacology, 29, 1558–1572.CrossRefGoogle ScholarPubMed
Danijua, Y., Bossong, M. G., Brandt, K., et al. (2020). Do the effects of cannabis on the hippocampus and striatum increase risk for psychosis? Neurosci Biobehav Rev, 112, 324–335.Google Scholar
Dekker, N., Schmitz, N., and Peters, B. D. (2010). Cannabis use and callosal white matter structure and integrity in recent-onset schizophrenia. Psychiatry Res, 181, 51–56.Google Scholar
Di Forti, M., Quattrone, D., Freeman, T. P., et al. (2019). The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): A multicentre case-control study. Lancet Psychiatry, 6, 427–436.Google Scholar
Dow-Edwards, D., and Silva, L. (2017). Endocannabinoids in brain plasticity: Cortical maturation, HPA axis function and behavior. Brain Res, 1654, 157–164.Google Scholar
Ferraro, L., La Cascia, C., Quattrone, D., et al. (2020). Premorbid adjustment and IQ in patients with first-episode psychosis: A multisite case-control study of their relationship with cannabis use. Schizophr Bull, 46, 517–529.Google Scholar
Ferraro, L., Russo, M., O’Connor, J., et al. (2013). Cannabis users have higher premorbid IQ than other patients with first onset psychosis. Schizophr Res, 150, 129–135.Google Scholar
French, E. D. (1997) delta9-Tetrahydrocannabinol excites rat VTA dopamine neurons through activation of cannabinoid CB1 but not opioid receptors. Neurosci Lett, 226, 159–162.Google Scholar
Gage, S. H., Hickman, M., and Zammit, S. (2016). Association between cannabis and psychosis: Epidemiologic evidence. Biol Psychiatry, 79, 549–556.Google Scholar
van de Giessen, E., Weinstein, J. J., Cassidy, C. M., et al. (2017). Deficits in striatal dopamine release in cannabis dependence. Mol Psychiatry, 22, 68–75.Google Scholar
Grant, I., Gonzalez, R., Carey, C. L., et al. (2003). Non-acute (residual) neurocognitive effects of cannabis use: A meta-analytic study. J Int Neuropsychol Soc, 9, 679–689.Google Scholar
Green, M. F. (1996). What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry, 153, 321–330.Google Scholar
Guimond, S., Gu, F., Shannon, H., et al. (2021). A diagnosis and biotype comparison across the psychosis spectrum: Investigating volume and shape amygdala-hippocampal differences from the B-SNIP study. Schizophr Bull, 47, 1706–1717.Google Scholar
Haney, M., and Evins, A. E. (2016). Does cannabis cause, exacerbate or ameliorate psychiatric disorders? An oversimplified debate discussed. Neuropsychopharmacology, 41, 393–401.Google Scholar
Hanna, R. C., Shalvoy, A., Cullum, C. M., et al. (2016). Cognitive function in individuals with psychosis: Moderation by adolescent cannabis use. Schizophr Bull, 42, 1496–1503.Google Scholar
Helle, S., Gjestad, R., Johnsen, E., et al. (2013). Cognitive changes in non-affective psychosis the first 4–6 weeks after admission to a psychiatric acute ward: Effects of substance use. Schizophr Bull, 39, 262.Google Scholar
Helle, S., Gjestad, R., Johnsen, E., et al. (2014). Cognitive changes in patients with acute phase psychosis: Effects of illicit drug use. Psychiatry Res, 220, 818–824.Google Scholar
Hibar, D. P., Westlye, L. T., and van Erp, T. G. M. (2016). Subcortical volumetric abnormalities in bipolar disorder. Mol Psychiatry, 21, 1710–1716.Google Scholar
Ho, N. F., Iglesias, J. E., Sum, M. Y., et al. (2017). Progression from selective to general involvement of hippocampal subfields in schizophrenia. Mol Psychiatry, 22, 142–152.Google Scholar
Houston, J. E., Murphy, J., Shevlin, M., et al. (2011). Cannabis use and psychosis: Re-visiting the role of childhood trauma. Psychol Med, 41, 2339–2348.Google Scholar
Hu, S. S., and Mackie, K. (2015). Distribution of the endocannabinoid system in the central nervous system. Handb Exp Pharmacol, 231, 59–93.Google Scholar
Huang, J. T.-J., Leweke, F. M., Tsang, T. M., et al. (2007). CSF metabolic and proteomic profiles in patients prodromal for psychosis. PLoS ONE, 2, e756.CrossRefGoogle ScholarPubMed
Ivleva, E. I., Clementz, B. A., and Dutcher, A. M. (2017). Brain structure biomarkers in the psychosis biotypes: Findings from the bipolar-schizophrenia network for intermediate phenotypes. Biol Psychiatry, 82, 26–39.Google Scholar
Keefe, R. S. E., Goldberg, T. E., Harvey, P. D., et al. (2004). The Brief Assessment of Cognition in Schizophrenia: Reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr Res, 68, 283–297.Google Scholar
Kendler, K. S., Ohlsson, H., Sundquist, J., et al. (2019). Prediction of onset of substance-induced psychotic disorder and its progression to schizophrenia in a Swedish national sample. Am J Psychiatry, 176, 711–719.CrossRefGoogle Scholar
Keshavan, M. S., Kelly, S., and Hall, M. H. (2020). The core deficit of ‘classical’ schizophrenia cuts across the psychosis spectrum. Can J Psychiatry, 65, 231–234.Google Scholar
Keshavan, M. S., Morris, D. W., Sweeney, J. A., et al. (2011). A dimensional approach to the psychosis spectrum between bipolar disorder and schizophrenia: The Schizo-Bipolar Scale. Schizophr Res, 133, 250–254.Google Scholar
Koenders, L., Machielsen, M. W. J., and van der Meer, F. J. (2015). Brain volume in male patients with recent onset schizophrenia with and without cannabis use disorders. J Psychiatry Neurosci, 40, 197–206.Google Scholar
Koethe, D., Giuffrida, A., Schreiber, D., et al. (2009). Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis. Br J Psychiatry, 194, 371–372.Google Scholar
Kraguljac, N. V., Karper, L. P., Seibyl, J. P., et al. (2017). Ketamine modulates hippocampal neurochemistry and functional connectivity: A combined magnetic resonance spectroscopy and resting-state fMRI study in healthy volunteers. Mol Psychiatry, 22, 562–569.Google Scholar
Krystal, J. H., Karper, L. P., Seibyl, J. P., et al. (1994). Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry, 51, 199–214.Google Scholar
Ksir, C., and Hart, C. L. (2016). Correlation still does not imply causation. Lancet Psychiatry, 3, 401.Google Scholar
Lee, T. T., Hill, M. N., and Lee, F. S. (2016). Developmental regulation of fear learning and anxiety behavior by endocannabinoids. Genes Brain Behav, 15, 108–124.Google Scholar
Leweke, F. M., Piomelli, D., Pahlisch, F., et al. (2012). Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry, 2, e94.Google Scholar
Lieberman, J. A., Girgis, R. R., Brucato, G., et al. (2018). Hippocampal dysfunction in the pathphysiology of schizophrenia: A selective review and hypothesis for early detection and intervention. Mol Psychiatry, 23, 1764–1772.Google Scholar
Loberg, E.-M., Helle, S., Nygard, M., et al. (2014). The cannabis pathway to non-affective psychosis may reflect less neurobiological vulnerability. Front Psychiatry, 5, 159.Google Scholar
Lubman, D. I., Cheetham, A., and Yucel, M. (2015). Cannabis and adolescent brain development. Pharmacol Ther, 148, 1–16.Google Scholar
Makowski, C., Bodnar, M., Shenker, J. J., et al. (2017). Linking persistent negative symptoms to amygdala-hippocampus structure in first-episode psychosis. Transl Psychiatry, 7, e1195.Google Scholar
Malchow, B., Hasan, A., Schneider-Axmann, T., et al. (2013). Effects of cannabis and familial loading on subcortical brain volumes in first-episode schizophrenia. Eur Arch Psychiatry Clin Neurosci, 263, S155–S168.Google Scholar
Mallet, J., Ramoz, N., Le Strat, Y., et al. (2017). Heavy cannabis use prior psychosis in schizophrenia: Clinical, cognitive and neurological evidences for a new endophenotype? Eur Arch Psychiatry Clin Neurosci, 267, 629–638.Google Scholar
Meyer, H. C., Lee, F. S., and Gee, D. G. (2018). The role of the endocannabinoid system and genetic variation in adolescent brain development. Neuropsychopharmacology, 43, 21–33.Google Scholar
Moghaddam, B., and Javitt, D. (2012). From revolution to evolution: The glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology, 37, 4–15.Google Scholar
Morrison, P. D., Zois, V., McKeown, D. A., et al. (2009). The acute effects of synthetic intravenous Delta9-tetrahydrocannabinol on psychosis, mood and cognitive functioning. Psychol Med, 39, 1607–1616.Google Scholar
O’Neill, A., Annibale, L., Blest-Hopley, G., et al. (2021). Cannabidiol modulation of hippocampal glutamate in early psychosis. J Psychopharmacol, 35, 814–822.CrossRefGoogle ScholarPubMed
Paul, S., and Bhattacharyya, S. (2021). Cannabis use-related working memory deficit mediated by lower left hippocampal volume. Addict Biol, 26, e12984.Google Scholar
Quattrone, D., Ferraro, L., Tripoli, G., et al. (2020). The Relation of the Psychosis Continuum with Schizophrenia Polygenic Risk Score and Cannabis Use. Schizophrenia International Research Society.Google Scholar
Rabin, R. A., Zakzanis, K. K., and George, T. P. (2011). The effects of cannabis use on neurocognition in schizophrenia: A meta-analysis. Schizophr Res, 128, 111–116.Google Scholar
Ranganathan, M., and D’Souza, D. C. (2006). The acute effects of cannabinoids on memory in humans: A review. Psychopharmacologia, 188, 425–444.Google Scholar
Rasetti, R., Sambataro, F., Chen, Q., et al. (2011). Altered cortical network dynamics: A potential intermediate phenotype for schizophrenia and association with ZNF804A. Arch Gen Psychiatry, 68, 1207–1217.Google Scholar
Raver, S. M., Haughwout, S. P., and Keller, A. (2013). Adolescent cannabinoid exposure permanently suppresses cortical oscillations in adult mice. Neuropsychopharmacology, 38, 2338–2347.CrossRefGoogle ScholarPubMed
del Re, E. C., Yassine, W., Zeng, V., et al. (2022). Childhood trauma and cannabis interactions in affecting psychosis onset: Role of the anterior–posterior axis of the hippocampus and differences in cannabis use before or after psychosis onset. medRxiv.Google Scholar
Realini, N., Rubino, T., and Parolaro, D. (2009). Neurobiological alterations at adult age triggered by adolescent exposure to cannabinoids. Pharmacol Res, 60, 132–138.Google Scholar
Renard, J., Krebs, M. O., Le Pen, G., et al. (2014). Long-term consequences of adolescent cannabinoid exposure in adult psychopathology. Front Neurosci, 8, 361.Google Scholar
Rentzsch, J., Stadtmann, A., Montag, C., et al. (2016). Attentional dysfunction in abstinent long-term cannabis users with and without schizophrenia. Eur Arch Psychiatry Clin Neurosci, 266, 409–421.Google Scholar
Rigucci, S., Xin, L., Klauser, P., et al. (2017). Cannabis use in early psychosis is associated with reduced glutamate levels in the prefrontal cortex. Psychopharmacologia, 235, 13–22.Google Scholar
Rubino, T., and Parolaro, D. (2008). Long lasting consequences of cannabis exposure in adolescence. Mol Cell Endocrinol, 286, S108–S113.Google Scholar
Rubino, T., and Parolaro, D. (2016). The impact of exposure to cannabinoids in adolescence: Insights from animal models. Biol Psychiatry, 79, 578–585.Google Scholar
Rubino, T., Prini, P., Piscitelli, F., et al. (2015). Adolescent exposure to THC in female rats disrupts developmental changes in the prefrontal cortex. Neurobiol Dis, 226, 159–162.Google Scholar
Sami, M. B., Annibale, L., O’Neill, A., et al. (2021). Eye movements in patients in early psychosis with and without a history of cannabis use. NPJ Schizophrenia, 7, 1–7.Google Scholar
Sami, M. B., and Bhattacharyya, S. (2018). Are cannabis-using and non-using patients different groups? Towards understanding the neurobiology of cannabis use in psychotic disorders. J Psychopharmacol, 32, 825–849.Google Scholar
Sami, M. B., Worker, A., Colizzi, M., et al. (2020). Association of cannabis with glutamatergic levels in patients with early psychosis: Evidence for altered volume striatal glutamate relationships in patients with a history of cannabis use in early psychosis. Transl Psychiatry, 10, 111.Google Scholar
Scheffler, F., Plessis, S. D., Asmal, L., et al. (2021). Cannabis use and hippocampal subfield volumes in males with a first episode of a schizophrenia spectrum disorder and healthy controls. Schizophr Res, 231, 13–21.Google Scholar
Schneider, M. (2008). Puberty as a highly vulnerable developmental period for the consequences of cannabis exposure. Addict Biol, 13, 253–263.Google Scholar
Schnell, T., Kleiman, A., Gouzoulis-Mayfrank, E., et al. (2012). Increased gray matter density in patients with schizophrenia and cannabis use: A voxel-based morphometric study using DARTEL. Schizophr Res, 138, 183–187.Google Scholar
Schoeler, T., Kambeitz, J., and Bhattacharyya, S. (2015) The effect of cannabis on memory function in users with and without a psychotic disorder: A meta-analysis. Psychol Med, 10, 1–12.Google Scholar
Shakory, S., Watts, J. J., Hafizi, S., et al. (2018). Hippocampal glutamate metabolites and glial activation in clinical high risk and first episode psychosis. Neuropsychopharmacology, 43, 2249–2255.CrossRefGoogle ScholarPubMed
Smith, M. J., Cobia, D. J., Reilly, J. L., et al. (2015). Cannabis-related episodic memory deficits and hippocampal morphological differences in healthy individuals and schizophrenia subjects. Hippocampus, 25, 1042–1051.Google Scholar
Solowij, N., Malterfang, M., Lubman, D. I., et al. (2013). Alteration to hippocampal shape in cannabis users with and without schizophrenia. Schizophr Res, 143, 179–184.Google Scholar
Stip, E. (2006). Cognition, schizophrenia and the effect of antipsychotics. Encephale, 32, 341–350.Google Scholar
Stirling, J., Lewis, S., and Hopkins, R., et al. (2005). Cannabis use prior to first onset psychosis predicts spared neurocognition at 10-year follow-up. Schizophr Res, 75, 135–137.Google Scholar
Stokes, P. R., Egerton, A., Watson, B., et al. (2012). History of cannabis use is not associated with alterations in striatal dopamine D2/D3 receptor availability. J Psychopharmacol, 26, 144–149.Google Scholar
Strasser, H. C., Lilyestrom, J., Ashby, E. R., et al. (2005). Hippocampal and ventricular volumes in psychotic and nonpsychotic bipolar patients compared with schizophrenia patients and community control subjects: A pilot study. Biol Psychiatry, 57, 633–639.Google Scholar
Sullivan, J. M. (2000). Cellular and molecular mechanisms underlying learning and memory impairments produced by cannabinoids. Learn Mem, 7, 132–139.Google Scholar
Szallasi, A., Cortright, D. N., Blum, C. A., et al. (2007). The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept. Nat Rev Drug Discov, 6, 357–372.Google Scholar
Tamminga, C. A., Clementz, B. A., Pearlson, G. D., et al. (2021). Biotyping in psychosis: Using multiple computational approaches with one data set. Neuropsychopharmacology, 46, 143–155.Google Scholar
Tamminga, C. A., Ivleva, E. I., Keshavan, M. S., et al. (2013). Clinical phenotypes of psychosis in the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP). Am J Psychiatry, 170, 1263–1274.Google Scholar
Tamminga, C. A., Pearlson, G. D., Keshavan, M., et al. (2014). Bipolar and schizophrenia network for intermediate phenotypes: Outcomes across the psychosis continuum. Schizophr Bull, 40, S131–S137.Google Scholar
Tanda, G., and Goldberg, S. R. (2003). Cannabinoids: Reward, dependence, and underlying neurochemical mechanisms – A review of recent preclinical data. Psychopharmacology (Berl), 232, 2723–2729.Google Scholar
Treadway, M. T., Waskom, M. L., Dillon, D. G., et al. (2015). Illness progression, recent stress, and morphometry of hippocampal subfields and medial prefrontal cortex in major depression. Biol Psychiatry, 77, 285–294.Google Scholar
van Tricht, M. J., Harmsen, E. C., Koelman, J. H. T. M., et al. (2013). Effects of cannabis use on event related potentials in subjects at ultra high risk for psychosis and healthy controls. Int J Psychophysiol, 88, 149–156.Google Scholar
Van Gastel, W. A., Schubart, C. D., Van Eijk, K. R., et al. (2013). The effect of childhood maltreatment and cannabis use on adult psychotic symptoms is modified by the COMT Val158Met polymorphism. Schizophr Res, 150, 303–311.Google Scholar
Volkow, N. D., Wang, G. J., Telang, F., et al. (2014). Decreased dopamine brain reactivity in marijuana abusers is associated with negative emotionality and addiction severity. Proc Natl Acad Sci USA, 111, E3149–E3156.CrossRefGoogle ScholarPubMed
Wannan, C. M. J., Cropley, V. L., Chakravarty, M. M., et al. (2019). Evidence for network-based cortical thickness reductions in schizophrenia. Am J Psychiatry, 176, 552–563.Google Scholar
Wiers, C. E., Shokri-Kojori, E., Wong, C. T., et al. (2016). Cannabis abusers show hypofrontality and blunted brain responses to a stimulant challenge in females but not in males. Neuropsychopharmacology, 41, 2596–2605.Google Scholar
Winterburn, J. L., Pruessner, J. C., Chavez, S., et al. (2013). A novel in vivo atlas of human hippocampal subfields using high-resolution 3 T magnetic resonance imaging. Neuroimage, 74, 254–265.CrossRefGoogle ScholarPubMed
Yucel, M., Bora, E., Lubman, D. I., et al. (2012). The impact of cannabis use on cognitive functioning in patients with schizophrenia: A meta-analysis of existing findings and new data in a first-episode sample. Schizophr Bull, 38, 316–330.Google Scholar
Zhou, Y., Shu, N., Liu, Y., et al. (2008). Altered resting-state functional connectivity and anatomical connectivity of hippocampus in schizophrenia. Schizophr Res, 100, 120–132.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×